Calumet Inc Dossier - Source-backed chat

Calumet Inc

CLMTNASDAQ

SectorMaterials

IndustrySpecialty Chemicals

Beta (adjusted)0.81

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $53.72Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $4.7B

Enterprise Value $6.8B

Shares Outstanding 87.4M diluted

Moat Rating None

Next Earnings Date9 Nov 2026

Last ex-dividend29 Jan 2016

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Calumet, Inc. is at a pivotal transition point, evolving from a highly leveraged specialty refiner into a leading North American sustainable aviation fuel (SAF) producer. The investment thesis centers on the successful execution of the MaxSAF 150 project at Montana Renewables and the steady cash flows from its core Specialty Products segment. However, the company's high leverage, historical operational volatility (such as the unplanned Shreveport outage in Q1 2026), and sensitivity to regulatory policy (EPA RVOs) balance the significant growth potential, justifying a Hold rating at current valuation levels.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$26.00

Mean target$42.20

High · most bullish analyst$60.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$26.0020%

Operational setbacks, such as recurring feedstock contamination or technical challenges at Montana Renewables, delay the SAF capacity ramp-up. A weakening regulatory environment or a drop in biofuel margins (e.g., lower RIN pricing) severely impacts profitability. High interest expenses and capital expenditures strain liquidity, raising solvency and refinancing concerns for upcoming debt maturities.

Base CaseCentral scenario

$42.2055%

Matches the consensus mean

Calumet successfully stabilizes operations at its Shreveport facility and progresses with the MaxSAF 150 expansion. Biofuel margins remain supported by the EPA's Set 2 RVOs, and the Specialty Products segment continues to generate steady cash flows. The company gradually deleverages, and the stock trades in line with its historical multiples and peer averages as institutional ownership increases post-C-Corp conversion.

Bull CaseUpside scenario

$60.0025%

Calumet achieves flawless execution of the MaxSAF 150 project, ramping up SAF production to 150 million gallons in 2026 and expanding to 300 million gallons by late 2029. Strong regulatory support (45Z tax credits remaining at $1.00/gallon) and robust commercial offtake agreements drive a rapid EBITDA expansion. The company utilizes its strong free cash flow to aggressively pay down $500 million in debt, leading to a structural re-rating of the stock.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Transition to a C-Corporation structure in mid-2024 removes barriers to institutional investment and passive index inclusion.
Montana Renewables' MaxSAF 150 project positions the company as a dominant player in the high-margin North American SAF market.
Core Specialty Products and Solutions segment provides a stable, cash-generative foundation with strong brand equity (TruFuel, Bel-Ray).
Favorable regulatory tailwinds from the EPA's Set 2 RVOs and reallocated small-refinery exemptions support biofuel margins.

Key Investment Risks

Highly leveraged capital structure with significant debt service obligations and upcoming maturities.
Operational and execution risks, as demonstrated by the unplanned Shreveport outage in Q1 2026 which reduced production by 750,000 barrels.
High sensitivity to regulatory policies, tax credits (45Z), and compliance market dynamics (RINs).
Feedstock cost volatility and potential supply chain disruptions for renewable lipids.

Thesis Invalidation Triggers

Significant delays or cost overruns in the MaxSAF 150 project execution beyond 2026.
A material reduction or elimination of regulatory incentives for sustainable aviation fuels and renewable diesel.
Inability to refinance upcoming debt maturities on reasonable terms, leading to covenant breaches.
Prolonged operational downtime at major manufacturing facilities like Shreveport or Great Falls.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.